Pediatrics Spanish Registry of Percutaneous Melody Pulmonary Valve Implantation in Patients Younger Than 18 Years.

Autor: Solana-Gracia R; Unidad de Cardiología Infantil, Hospital Universitario Infanta Leonor, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Electronic address: ruth.solana@salud.madrid.org., Rueda F; Unidad de Cardiología Infantil, Hospital Universitario A Coruña, A Coruña, Spain., Betrián P; Servicio de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Gutiérrez-Larraya F; Servicio de Cardiología Infantil, Hospital Universitario La Paz, Madrid, Spain., Del Cerro MJ; Servicio de Cardiología Infantil, Hospital Universitario Ramón y Cajal, Madrid, Spain., Pan M; Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain., Alcíbar J; Servicio de Cardiología, Hospital Universitario de Cruces, Bilbao, Vizcaya, Spain., Coserría JF; Servicio de Cardiología Infantil, Hospital Virgen del Rocío, Sevilla, Spain., Velasco JM; Instituto Pediátrico del Corazón, Hospital Universitario 12 de Octubre, Madrid, Spain., Zunzunegui JL; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Unidad de Cardiología Infantil, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Jazyk: English; Spanish; Castilian
Zdroj: Revista espanola de cardiologia (English ed.) [Rev Esp Cardiol (Engl Ed)] 2018 Apr; Vol. 71 (4), pp. 283-290. Date of Electronic Publication: 2017 Oct 16.
DOI: 10.1016/j.rec.2017.07.013
Abstrakt: Introduction and Objectives: A decade has passed since the first Spanish percutaneous pulmonary Melody valve implant (PPVI) in March 2007. Our objective was to analyze its results in terms of valvular function and possible mid-term follow-up complications.
Methods: Spanish retrospective descriptive multicenter analysis of Melody PPVI in patients < 18 years from the first implant in March 2007 until January 1, 2016.
Results: Nine centers were recruited with a total of 81 PPVI in 77 pediatric patients, whose median age and weight were 13.3 years (interquartile range [IQR], 9.9-15.4) and 46kg (IQR, 27-63). The predominant cardiac malformation was tetralogy of Fallot (n = 27). Most of the valves were implanted on conduits, especially bovine xenografts (n = 31). The incidence of intraprocedure and acute complications was 6% and 8%, respectively (there were no periprocedural deaths). The median follow-up time was 2.4 years (IQR, 1.1-4.9). Infective endocarditis (IE) was diagnosed in 4 patients (5.6%), of which 3 required surgical valve explant. During follow-up, the EI-related mortality rate was 1.3%. At 5 years of follow-up, 80% ± 6.9% and 83% ± 6.1% of the patients were free from reintervention and pulmonary valve replacement.
Conclusions: Melody PPVI was safe and effective in pediatric patients with good short- and mid-term follow-up hemodynamic results. The incidence of IE during follow-up was relatively low but was still the main complication.
(Copyright © 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: